Key issues in inhibitor management in patients with haemophilia

Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s319-29. doi: 10.2450/2013.0246-12. Epub 2013 Dec 3.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Blood Coagulation Factors / therapeutic use
  • Disease Management
  • Dose-Response Relationship, Immunologic
  • Factor IX / genetics
  • Factor IX / immunology*
  • Factor IX / therapeutic use
  • Factor VIII / genetics
  • Factor VIII / immunology*
  • Factor VIII / therapeutic use
  • Factor VIIa / therapeutic use
  • Genetic Predisposition to Disease
  • Hemophilia A / genetics
  • Hemophilia A / immunology*
  • Hemophilia A / therapy
  • Hemophilia B / genetics
  • Hemophilia B / immunology*
  • Hemophilia B / therapy
  • Humans
  • Immunization
  • Immunosuppression Therapy / methods
  • Isoantibodies / immunology*
  • Multicenter Studies as Topic
  • Mutation, Missense
  • Phenotype
  • Primary Prevention
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins / immunology
  • Recombinant Proteins / therapeutic use
  • Risk Factors

Substances

  • Blood Coagulation Factors
  • Isoantibodies
  • Recombinant Proteins
  • prothrombin complex concentrates
  • Factor VIII
  • Factor IX
  • recombinant FVIIa
  • Factor VIIa